Anti-IL-23 Monoclonal Antibody Synergizes in Combination with Targeted Therapies or IL-2 to Suppress Tumor Growth and Metastases
Open Access
- 14 March 2011
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 71 (6), 2077-2086
- https://doi.org/10.1158/0008-5472.can-10-3994
Abstract
Immunosuppressive barricades erected by tumors during the evolution of immune escape represent a major obstacle to many potentially effective cancer therapies and vaccines. We have shown that host interleukin (IL)-23 suppresses the innate immune response during carcinogenesis and metastasis, independently of effects on the proinflammatory cytokine IL-17A. Based on these findings, we envisioned that IL-23 neutralization might offer a promising strategy to modulate immunosuppression, particularly in combination with immunostimulatory agents. Here we show that by itself a neutralizing monoclonal antibody (mAb) to IL-23 suppressed early experimental lung metastases in the B16F10 mouse model of melanoma and also modestly inhibited the subcutaneous growth of primary tumors. These antitumor effects were respectively mediated by natural killer cells or CD8+ T cells. More notably, combinatorial treatments of anti-IL-23 mAb with IL-2 or anti-erbB2 mAb significantly inhibited subcutaneous growth of established mammary carcinomas and suppressed established experimental and spontaneous lung metastases. Overall, our results suggest the potential of anti-human IL-23 mAbs to improve the immunostimulatory effects of IL-2 and trastuzumab in the current management of some advanced human cancers. Cancer Res; 71(6); 2077–86. ©2011 AACR.Other Versions
This publication has 30 references indexed in Scilit:
- Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC developmentBritish Journal of Cancer, 2010
- Interleukin-23 Drives Intestinal Inflammation through Direct Activity on T CellsImmunity, 2010
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive ImmunityCancer Cell, 2010
- Chemotherapy and radiotherapy: Cryptic anticancer vaccinesSeminars in Immunology, 2010
- IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasisProceedings of the National Academy of Sciences, 2010
- Features of responding T cells in cancer and chronic infectionCurrent Opinion in Immunology, 2010
- Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune responseProceedings of the National Academy of Sciences, 2008
- Rapid tolerization of virus-activated tumor-specific CD8 + T cells in prostate tumors of TRAMP miceProceedings of the National Academy of Sciences of the United States of America, 2008
- Overcoming obstacles to the effective immunotherapy of human cancerProceedings of the National Academy of Sciences of the United States of America, 2008
- Cancer-related inflammationNature, 2008